Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy

NCT01657604 is registered in ClinicalTrials.gov with University of Jena as lead sponsor.

NCT NCT01657604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01657604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Lead sponsor
University of Jena
Phase
Phase 3
Overall status
Completed
Start date
August 24, 2012
Completion date
May 31, 2022
Enrollment
717 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia